The EU Health Technology Assessment (HTA) Regulation presents new avenues for companies seeking scientific advice on their health technologies. While not all companies will have access to joint scientific consultations at the EU level, success remains achievable through proactive engagement with national agencies. This is according to Alexander Natz of EUCOPE.
Natz suggests that companies should strategically engage with national agencies early in the process. This provides a viable substitute for the EU-level advice that may not be accessible to all. This approach allows companies to receive vital feedback and guidance, potentially smoothing the path toward market access for their products.
This photo shows Stefano Benvenuti, Henriette Burghoorn, Paolo Morgese, Marcus Droege, Stijn Heessen, and Alexander Natz at the Advanced Therapies Congress in London, 2025 (Norstella).
